"Goldengoph, we may have to wait a little for the kaboom. It is only a matter of time and I believe a short time. Just my opinion."
And it's just my opinion that the only kaboom, apart from the odd manufactured mini-pump 'n dump, will be the sound of Biophan imploding as it sinks into bankruptcy once its "management", owners (such as TI, Biomed and other Weiner-associated vehicles)and other known associates have stripped all the cash and other assets worth having from the poor shareholders who've been gulled into holding these shares, and even into voting into allowing the "management" to issue another 550 million shares.
That's just my opinion, but at least my opinion has the merit of being underpinned by both the pps and the previous track record of BIPH's well-paid but underperforming "management".
Unlike the opinions of the "Biophan will make us all rich dead soon" school of thought, which seems to be underpinned by nothing more than wild optimism coupled with an inability to learn from experience.
Or maybe in the immortal words of Upton Sinclair:
"It is very difficult to get someone to believe something when his salary depends on his not believing it"
Whatever.
But, look! Here's some good news:
"Biophan Announces Acceleration of Commercialization of MYO-VAD™ Cardiac Assist Device
December 08, 200x 07:14 AM US Eastern Timezone
Company details plans for utilization of funds to be invested in MYOTECH under acquisition agreement.
ROCHESTER, N.Y.--(BUSINESS WIRE)--Dec. 8, 2005--Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation biomedical technology, today announced the acceleration of the commercialization program of the MYO-VAD following the recently announced agreement for its acquisition and investment in MYOTECH, LLC.
MYOTECH will ...... step up the development of the first generation MYO-VAD, a device designed to quickly restore cardiac output in patients suffering from many forms of heart failure."
Sad thing is, this "good news" is from 2005. And the Myotech CSS device? Still at least two years away from commercialization, just as it ever was. Not even in human studies yet, in fact. Or discussed with FDA.
Kaboom, indeed.
